Madhukar Patel, MD
Surgery · Dallas, TXNPI 1659635126
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.3%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by AstraZeneca at 55.3% of the total. Reporting peaked in 2022 at $5,798 and has fallen 55.1% since, to $2,602 in 2025.
Across 21 payments — averaging $623.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$7K
- Transmedics, Inc.$5K
- Integra Lifesciences Corporation$183
- Genentech, Inc.$132
- Veloxis Pharmaceuticals, Inc.$130
- Sirtex Medical Inc$105
- plus $170 from 3 others
What the payments were for
- Consulting fees$6,98153%
- Travel & lodging$5,13539%
- Food & beverage$9727%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 8 | $7,232 |
| Transmedics, Inc. | 5 | $5,135 |
| Integra Lifesciences Corporation | 2 | $183 |
| Genentech, Inc. | 1 | $132 |
| Veloxis Pharmaceuticals, Inc. | 1 | $130 |
| Sirtex Medical Inc | 1 | $105 |
| Johnson & Johnson | 1 | $83 |
| Clozex Medical Inc | 1 | $73 |
| Medtronic | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$5,370
- ORGAN CARE SYSTEM$5,135
- TECENTRIQ$132
- Envarsus$130
- CODMAN CERTAS$117
- CUSA CLARITY$117
- CODMAN HAKIM$117
- DURASEAL EXACT SPINAL SEALANT SYSTEM$117
- SIR-Spheres Microspheres$105
- IMJUDO$102
How this compares
$13,089 in reported general payments places this provider in the 75th percentile of 1,830 surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Valganciclovir Hcl | 38 | $8,220 |
| Ursodiol | 64 | $2,500 |
| Humalog Kwikpen U-100Insulin Lispro | 20 | $1,505 |
| Humulin N KwikpenInsulin Nph Human Isophane | 17 | $1,462 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 18 | $1,215 |
| Novolin N FlexpenInsulin Nph Human Isophane | 11 | $631 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 74 | $465 |
| Tamsulosin Hcl | 20 | $179 |
| Atorvastatin Calcium | 28 | $122 |
| Prednisone | 11 | $118 |
| Hydroxychloroquine Sulfate | 11 | $117 |
| Furosemide | 17 | $86 |
| Carvedilol | 19 | $84 |
| Pantoprazole Sodium | 16 | $65 |
| Methocarbamol | 13 | $56 |
Paid to pharmacies, not to this prescriber.
Other surgery in Dallas
- Sachin KukrejaDallas$640K
- Walton TaylorDallas$369K
- Steven LeedsDallas$193K
- Aaron HoffmanDallas$185K
- Lam leDallas$180K
- Bola AladegbamiDallas$91K
- Michael HarkinsTomball$2.7M
- Douglas StoddardAustin$1.4M
- Steven FassAustin$989K
- Vineet ChoudhryAustin$851K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.